Efficacy and safety of platelet additive solution‐E stored platelet concentrates
Transfusion · 2023
DOI: 10.1111/trf.17583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2023. Verfasst von Saskia E Spelmink und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Transfusion Reaction, Hypersensitivity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Terumo BCT.
Abstract (Originalsprache)
Introduction
In 2018, platelet (PLT) additive solution‐E (PAS‐E) was introduced. The implementation of PAS‐E was expected to diminish the number of allergic reactions in recipients following a PLT transfusion. Here, we evaluated the efficacy and safety of transfusions with PLTs stored in PAS‐E. Study Design and Methods After implementation of PAS‐E, data were collected from 2 cohorts of patients with hematological disorders as well as oncology patients, receiving PLTs in PAS‐E. A similar patient group in a recent RCT, receiving PLTs in plasma, was used as a historical control group for both cohorts. Endpoints were corrected count increments (CCIs), bleeding scores (only reported in cohort 1), and the incidence of adverse reactions.
Results
In cohort 1, the mean 1‐h CCI was 14.3 ± 6.9, and the 24‐h CCI was 8.7 ± 5.6. In cohort 2, the 1‐h CCI was 11.6 ± 7.8 and the 24‐h CCI was 7.0 ± 6.1. In the control group, the 1‐h CCI was 15.4 ± 5.5 and 24‐h CCI 8.7 ± 4.8. Bleeding complications of WHO grade ≥2 occurred in 40% of patients in cohort 1 compared to 44% in plasma PCs. The incidence of adverse reactions was 1.2% in the two PAS‐E cohorts, compared to 3.0% in plasma PCs. National hemovigilance data showed a significant reduction in allergic reactions with PAS‐E PC transfusions as compared to plasma PCs with an odds ratio of 0.46 (CI 95% 0.37–0.58).
Conclusion
The CCIs of PLTs in PAS‐E were decreased compared to plasma PCs, but clinically acceptable. Allergic transfusion reactions were decreased in PAS‐E PCs compared to plasma PCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, The Netherlands.
- Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
- Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, The Netherlands.
- Department of Laboratory Medicine, Amphia Hospital, Breda, The Netherlands.
- TRIP (Transfusion and Transplantation Reactions in Patients) Hemovigilance and Biovigilance Office, Leiden, The Netherlands.
ORCID-Profile: Saskia E Spelmink, Leo van de Watering, Adriaan J van Gammeren
Förderung
- Terumo BCT
Zitieren
APA
Spelmink, S. E., Jager, S. T., van de Watering, L., van der Meer, P. F., van Gammeren, A. J., Wiersum-Osselton, J. C., Klei, T. R. L., Kerkhoffs, J. H., & PAS-E Research group (2023). Efficacy and safety of platelet additive solution‐E stored platelet concentrates. Transfusion. https://doi.org/10.1111/trf.17583
Vancouver
Spelmink SE, Jager ST, van de Watering L, van der Meer PF, van Gammeren AJ, Wiersum-Osselton JC, et al. Efficacy and safety of platelet additive solution‐E stored platelet concentrates. Transfusion. 2023. doi:10.1111/trf.17583
BibTeX
@article{Spelmink2023,
author = {Spelmink, Saskia E and Jager, Suzanne T and van de Watering, Leo and van der Meer, Pieter F and van Gammeren, Adriaan J and Wiersum-Osselton, Johanna C and Klei, Thomas R L and Kerkhoffs, Jean-Louis H and PAS-E Research group, PAS-E Research group},
title = {Efficacy and safety of platelet additive solution‐E stored platelet concentrates},
journal = {Transfusion},
year = {2023},
doi = {10.1111/trf.17583}
}
EUVIMED